All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1800+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Siemens Healthineers receives FDA clearance for two new photon-counting CT scanners, expanding their Naeotom Alpha family for more detailed imaging
CT imaging - Read more

THE GOOD
Business Development

Endo sells international pharmaceutical business to Knight Therapeutics for up to $99M as part of restructuring effort
Divestiture, opioid - Read more

Coherus sees 30% of their staff (50 employees) move to Intas following $483.4M Udenyca (targeting G-CSF; Neulasta biosimilar, Amgen) sale
Staff transfer, biosimilar, pegylated peptide, febrile neutropenia, acute radiation syndrome - Read more

Viking Therapeutics pays $150M to secure CordenPharma's production capacity for obesity hopeful VK2735 (targeting GLP-1, GIP)
Supply chain, drug supply deal, GLP-1, obesity - Read more

PRESENTED BY YOU?
Get the attention of 1800+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Clinical Trials

CervoMed delivers positive Ph2b data for neflamapimod (p38 alpha inhibitor) in dementia with Lewy bodies
Small molecule, dementia with Lewy bodies - Read more

Gilead Sciences' lenacapavir, shows promise as once-yearly PrEP in a small Ph1 trial
Prophylaxis, small molecule, human immunodeficiency virus (HIV) - Read more

Protagonist Therapeutics and Johnson & Johnson's icotrokinra (IL-23 receptor antagonist) delivers positive results in Ph2b study for ulcerative colitis
Small molecule, ulcerative colitis - Read more

THE GOOD
Fundraises

Mineralys Therapeutics $250M public offering, developing medicines for hypertension, CKD, OSA and other aldosterone-related diseases
Small molecule, hypertension, chronic kidney disease, sleep apnea - Read more

Neuromod $10.8M Series B expansion, commercializing tinnitus treatment device Lenire in US and Europe.
Medical device, tinnitus - Read more

MSInsight €1.6M ($1.75M) Seed, precision medicine in oncology for regulatory clinical validation
Precision medicine, cancer detection/screening, AI, bioinformatics - Read more

Acurx Pharmaceuticals $1.1M registered direct offering, developing novel antibiotics for difficult-to-treat bacterial infections
Small molecule, antibiotic, bacterial infection - Read more

THE GOOD
Investments

Merck & Co. opens $1B vaccine plant in North Carolina, part of its $20B investment in US manufacturing by 2028
Vaccine, new facility, vaccine manufacturing - Read more

Almac opens $83.7M UK plant for oral treatments, enhancing capacity for oncology therapies and patient-centric drugs
CDMO (Contract Development & Manufacturing Organization), new facility, oral manufacturing - Read more

Entos Pharmaceuticals secures $77.5M from Canadian and Alberta governments for $198.5M biomanufacturing facility in Edmonton to advance Fusogenix PLV therapeutics
Biomanufacturing, facility build, public funding, drug delivery - Read more

THE GOOD
Lawsuits

Judge dismisses 200+ lawsuits against Merck, ruling Gardasil vaccine warnings couldn't be changed without stronger evidence
Vaccine, cervical cancer, vaccine suit - Read more

THE GOOD
Marketing

Innovaderm Research rebrands as Indero, expanding focus from dermatology to include rheumatology due to overlapping immune-mediated conditions
CRO (Contract Research Organization), rebrand - Read more

THE GOOD
Mergers & Acquisition

Bristol Myers Squibbs acquires 2seventy bio, gaining full rights to Abecma (targeting BCMA) CAR-T therapy, for $286 million
Cell therapy, CAR-T, cancer - Read more

Archimed acquires BioVendor Group, a developer of diagnostic products with operations across Europe
Immunoassays, diagnostics - Read more

THE GOOD
Partnerships

Saniona, Boehringer Ingelheim extend ion channel research collaboration for developing schizophrenia cognitive impairment treatments
Research & Development, drug discovery, schizophrenia - Read more

NEC Corporation, DEJIMA Infectious Disease Research Alliance, CEPI, partnership to develop tick-borne virus vaccine using AI and Nanoball technology
Vaccine, drug development, severe fever with thrombocytopenia syndrome (SFTS), research & development, drug delivery, AI - Read more

Zealand Pharma, Roche partner to develop and (eventually) co-commercialize petrelintide for obesity treatment with $1.65B upfront and profit-sharing agreement
Peptide, obesity, drug development, commercialization - Read more

RoslinCT, Ayrmid strategic partnership for manufacturing FDA-approved cell therapy Omisirge at RoslinCT's Massachusetts facility
CDMO (Contract Development & Manufacturing Organization), cell therapy manufacturing, stem cell-derived therapy, allogeneic cell therapy, cell therapy, cancer, manufacturing partnership - Read more

THE GOOD
Politics & Policy

DOGE chainsaw spares FDA's medical product review units (for now)
Food & Drug Administration (FDA), drug approval process, facility inspection - Re ad more [Paywall]

THE GOOD
Product Launches

Boehringer Ingelheim launches One Medicine Platform using Veeva's technology to unify data and accelerate drug development
Drug development, platform technology, software - Read more

THE GOOD
Research

CU Anschutz researchers develop enhanced CAR-T cell therapy (ALA-CART) to better target resistant cancer cells
Cell therapy, CAR-T, cancer - Read more

PRESENTED BY TLDR BIOTECH
What would you do with 6.5k+ meticulously tagged biotech & pharma data points?

Over the past year, TLDR Biotech has been collecting and categorizing industry news across approvals, clinical trials, fundraises, partnerships, M&A, politics & policy, and much much more.

Each data point is tagged by drug modality, disease indication, tech area, and even more specific categories. For example:

🔍 Need to track all small molecule fundraises across oncology?

📈 Want a curated list of recent cell therapy clinical trials updates (both the successes and failures)?

💡 Looking for trends in Alzheimer's and Parkinson's disease partnerships?

We’re leveraging this resource to build tailored reports and curated insights for select clients—and we’re opening up limited access to interested parties.

If you’re interested, send us an email [email protected] with the subject line “6K BIOTECH DATA” and we’ll chat further.*

*If you’ve received this newsletter as an email, just hit reply!

THE BAD
Clinical Trials

Pfizer and Arvinas's vepdegestrant (targeting ER) delivers limited mixed Ph3 results, progression-free survival improvement only found in ESR1-mutated breast cancer patients, but not in overall trial population
Small molecule, breast cancer - Read more

THE BAD
Earnings & Finances

Illumina cuts $100 million in costs and lowers 2025 profit outlook after China bans imports of its genetic sequencers amid trade tensions
Next-generation sequencing (NGS), diagnostics - Read more

THE BAD
Layoffs

Inozyme Pharma reduces workforce by 25%
ENPP1 deficiency, ABCC6 deficiency, enzyme - Read more

THE BAD
Regulatory

FDA pauses action against compounders making Wegovy copies until court rules on challenge to semaglutide's removal from shortage list
Compounding, GLP-1, obesity - Read more

THE BAD
Strategic Plans

Roche reorganizing and absorbing Spark Therapeutics with $2.4B impairment
Gene therapy, big pharma earnings, impairment charge - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here